ADVM - NASDAQ

Adverum Biotechnologies, Inc.

ADVM·NASDAQ

$4.36

+0.0000%

HealthcareBiotechnology

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$96.26M

EPS-6.6200

P/E Ratio-0.71

Earnings Date04/21/2026

179.84M

Assets

15%

3Y-59.0%

5Y-19.0%

10Y-32.0%

109.13M

Total Liabilities

23%

3Y-12.0%

5Y+128.0%

10Y+831.0%

70.71M

Total Equity

3Y-78.0%

5Y-60.0%

10Y-72.0%

Adverum Biotechnologies, Inc. Funding & Solvency Profile

ADVM · NASDAQ

Current Assets

Cash & Cash Equivalents60.65M

Net Receivables0.00

Inventory0.00

Other Current Assets5.61M

Total Current Assets131 M

Non-Current Assets

Property, Plant & Equipment45.22M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets3.32M

Total Non-Current Assets49 M

Total Assets

179.84M

Financial Health Analysis

Current Ratio

5.73x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.54x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

108 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

73% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Adverum Biotechnologies, Inc. Balance Sheet

ADVM • NASDAQ

Adverum Biotechnologies, Inc. Balance Sheet	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	60.7M	75M	68.4M	34.2M	62.4M	65.9M	154.9M	70.5M	222.2M	259.1M	159.4M	564K	357K
Short-Term Investments	65M	21.5M	117.2M	271M	367.3M	100.1M	50.1M	120M	0.0	37.7M	0.0	0.0	0.0
Cash & Short-Term Investments	125.7M	96.5M	185.6M	305.2M	429.7M	166M	205.1M	190.5M	222.2M	259.1M	159.4M	564K	357K
Net Receivables	0.0	0.0	0.0	5.7M	0.0	0.0	0.0	0.0	886K	449K	0.0	8K	1K
Accounts Receivables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	886K	449K	0.0	8K	1K
Other Receivables	0.0	0.0	0.0	5.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	4.7M	9.8M	3.7M	3.3M	2.2M	1.5M	874K	250K	24K
Other Current Assets	5.6M	6.2M	5M	6.2M	0.0	0.0	3.7M	3.3M	0.0	0.0	874K	0.0	0.0
Total Current Assets	131.3M	102.8M	190.6M	317.1M	434.4M	175.9M	208.8M	193.7M	225.3M	261M	160.3M	822K	382K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	45.2M	49.8M	113.9M	119.1M	47.1M	45.8M	3.6M	3M	4.2M	3.2M	1.1M	69K	4K
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5M	5M	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5M	5M	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	2.5M	3.3M	0.0	999K	999K	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	3.3M	3.2M	1.4M	250K	1M	11K	156K	140K	140K	140K	543K	194K	0.0
Total Non-Current Assets	48.5M	53M	117.8M	122.6M	48.1M	46.9M	4.7M	8.2M	9.3M	3.3M	1.6M	263K	4K
Total Assets	179.8M	155.8M	308.4M	439.7M	482.6M	222.7M	213.5M	201.9M	234.6M	264.3M	161.9M	1.1M	386K
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.7M	2M	2.5M	2.7M	2.9M	4.1M	1.7M	1.7M	1.5M	605K	951K	769K	522K
Accounts Payable	1.6M	1.9M	2.2M	1.4M	2.8M	4.1M	1.7M	1.7M	1.5M	605K	951K	769K	522K
Other Payables	123K	101K	254K	1.3M	40K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	9.5M	3.7M	7.4M	9.2M	3.9M	4.6M	2.9M	2.3M	2.6M	1.9M	1.5M	162K	117K
Short Term Debt	0.0	0.0	0.0	1.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	5.7M	5.5M	13.2M	0.0	4.5M	4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	123K	101K	254K	1.3M	40K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	8.6M	-100K	1.9M	1.9M	883K	813K	0.0	0.0
Other Current Liabilities	6M	8.8M	9.1M	7.5M	9.6M	-1.9M	6.1M	4.8M	4M	3.2M	2.2M	231K	200K
Total Current Liabilities	22.9M	20M	32.2M	21.3M	20.9M	19.4M	10.7M	10.7M	9.9M	6.6M	5.5M	1.2M	839K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	28.2M	0.0	0.0	0.0	0.0	0.0	91K	521K
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3M	7.1M	4.7M	6.6M	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3M	1.3M	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	192K	0.0	1M	1.1M	1.1M	0.0	1.4M	703K	738K	447K	306K	50K	23K
Total Non-Current Liabilities	86.2M	68.6M	94.6M	102.2M	27.3M	28.4M	1.6M	7.2M	9.1M	5.2M	7M	141K	544K
Capital Lease Obligations	91.7M	74M	106.8M	101.1M	30.7M	32.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	109.1M	88.5M	126.9M	123.5M	48.2M	47.8M	12.3M	17.9M	19M	11.7M	12.4M	1.3M	1.4M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	161.9M	8M	2.5M
Common Stock	2K	1K	10K	10K	10K	7K	6K	5K	4K	3K	2K	0.0	0.0
Additional Paid-In Capital	1.1B	1B	985.7M	965M	937.1M	560.7M	522.5M	439M	413.5M	336.8M	186.2M	632K	117K
Retained Earnings	-1.1B	-936M	-802.6M	-648.1M	-502.5M	-385M	-320.5M	-254.1M	-197.9M	-84.2M	-36.7M	-8.9M	-3.6M
Accumulated Other Comprehensive Income/Loss	-407K	-473K	-1.5M	-714K	-261K	-725K	-799K	-963K	-7K	-11K	10K	27K	8K
Total Stockholders' Equity	70.7M	67.2M	181.5M	316.2M	434.3M	175M	201.2M	184M	215.6M	252.6M	149.5M	-218K	-997K
Total Equity	70.7M	67.2M	181.5M	316.2M	434.3M	175M	201.2M	184M	215.6M	252.6M	149.5M	-218K	-997K
SUMMARY
Total Liabilities & Equity	179.8M	155.8M	308.4M	439.7M	482.6M	222.7M	213.5M	201.9M	234.6M	264.3M	161.9M	1.1M	386K
Total Investments	65M	21.5M	119.7M	274.3M	367.3M	100.1M	50.1M	120M	0.0	37.7M	0.0	0.0	0.0
Total Debt	91.7M	74M	106.8M	103M	30.7M	32.2M	300K	400K	0.0	0.0	0.0	0.0	485K
Net Debt	31.1M	-959K	38.4M	68.8M	-31.7M	-33.6M	-154.6M	-70.1M	-222.2M	-259.1M	-159.4M	-564K	128K
Shares Outstanding	20,984,200	20,984,200	20,984,200	20,984,200	20,984,200	20,984,200	20,984,200	20,984,200	20,984,200	20,984,200	20,984,200	20,984,200	20,984,200

SEC Filings

ADVM - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2025 N/A	December 09, 2025	December 09, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 04, 2025	December 04, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 21, 2025	November 19, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 24, 2025	October 24, 2025	2025	View Filing
8-K 8-K 2025 N/A	September 22, 2025	September 22, 2025	2025	View Filing
10-Q 10-Q 2025 Q2 Q2	August 12, 2025	June 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	August 12, 2025	August 12, 2025	2025	View Filing
8-K 8-K 2025 N/A	June 18, 2025	June 17, 2025	2025	View Filing
10-Q 10-Q 2025 Q1 Q1	May 14, 2025	March 31, 2025	2025	View Filing

Showing 1 to 10 of 233 filings

Related Guides

Blog Categories

Continue your ADVM research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.